Magic mushrooms can cause seizures, but the risk is low and concentrated in specific circumstances rather than spread evenly across all users. Psilocybin, the active compound, lowers the brain's seizure threshold in a dose-dependent way, and animal studies show convulsions only at doses far above typical recreational amounts. Human case reports exist but are rare, and most involve confounders like lithium use, stimulant co-use, or pre-existing epilepsy. For a healthy adult taking a moderate dose alone, the absolute risk appears well under 1 percent, though nobody has run the large prospective study that would pin the number down.
The mechanism: how psilocybin pushes neurons toward firing
Psilocybin is a prodrug. Your liver converts it to psilocin, which binds serotonin 5-HT2A receptors throughout the cortex. That binding drives the visual and cognitive effects, but it also changes how cortical neurons synchronize. Seizures are, at bottom, a failure of excitation-inhibition balance, and serotonergic drugs can tip that balance in either direction depending on dose and brain state.
At moderate doses, 5-HT2A activation tends to increase excitatory drive in layer 5 pyramidal neurons while simultaneously recruiting inhibitory interneurons. The net effect in a healthy brain is usually stable. At high doses, or in a brain with a lowered threshold already, the excitatory side can win. Psilocin also modestly raises extracellular glutamate and alters GABAergic signaling, both of which matter for seizure generation.
The dose relationship is steep. In rodent models, psilocybin produced convulsions only at doses roughly 10 to 50 times the equivalent of a human recreational dose, per preclinical work summarized in 2017 psychopharmacology reviews. That gap is the single most reassuring number in this topic. In plain terms: the brain has a wide margin before psilocybin alone flips it into a seizure.
One counterintuitive detail: psilocybin is not a classic convulsant like a GABA antagonist. It does not directly strip away inhibition. Instead it works indirectly, through serotonergic modulation of cortical networks, which is why seizures from mushrooms alone are so uncommon compared with seizures from stimulants or withdrawal states.
How often seizures actually occur: the quantified context
Exact incidence is unknown because there is no registry and no prospective cohort. What exists are case reports, poison center data, and emergency department surveys. Each gives a different frame.
| Data source | Seizure signal | Context |
|---|---|---|
| Published case reports (1960s–2020s) | Fewer than 30 documented cases worldwide | Most had co-ingestants or epilepsy |
| US poison center exposures, psilocybin | Under 1 percent of exposures coded seizure | Out of thousands of annual calls |
| ED visits involving hallucinogens | Seizure listed in low single-digit percent | Often polysubstance |
| Controlled human trials | Zero seizures in thousands of doses | Screened healthy volunteers |
| Rodent convulsion threshold | 10–50x human recreational dose | Preclinical only |
The controlled-trial figure deserves emphasis. Modern psilocybin trials have administered doses up to 30 mg in supervised settings, with thousands of participant-doses logged across the 2010s and 2020s, and reported essentially no seizures in screened healthy volunteers. That is a strong signal that the drug alone, in a healthy brain, rarely crosses the threshold.
Poison center data tells a different story because it captures the messy real world. Calls involve people who took mushrooms plus alcohol, plus MDMA, plus prescription drugs. Seizures in those calls are a small percentage, and disentangling psilocybin's contribution from the co-ingestants is often impossible.
Risk factors that turn a low baseline into a real hazard
The baseline risk is low. Certain conditions move a person from that baseline into a genuinely elevated category.
Epilepsy is the clearest. A person with diagnosed seizure disorder has a brain already sitting near threshold. Any serotonergic or glutamatergic perturbation, including psilocybin, can trigger an event. There is no good evidence that psilocybin is safe in uncontrolled epilepsy, and most trial protocols exclude it outright.
Lithium is the most dangerous interaction and the least known. Case reports since the 2000s describe seizures and severe reactions when people on lithium carbonate took psilocybin. Lithium lowers seizure threshold on its own, and the combination appears to compound risk. This is a professional caveat worth repeating: lithium plus mushrooms is not a casual combination.
Stimulant co-use matters too. Cocaine, methamphetamine, and high-dose caffeine all lower seizure threshold independently. Someone who takes mushrooms at the end of a stimulant binge is at far higher risk than the mushroom alone would suggest.
Other factors include sleep deprivation, alcohol withdrawal, head injury history, and high fever. Each removes a bit of the brain's buffer. Stacking several is where case reports cluster.
Red flags that warrant emergency care after a seizure:
- A seizure lasting longer than 5 minutes, or repeated seizures without recovery in between
- Seizure in someone with no prior seizure history who took mushrooms
- Confusion, fever, or stiff neck following the event
- Known lithium, stimulant, or antidepressant MAOI co-use
- Seizure in a pregnant person at any point
- Any seizure with injury, drowning risk, or breathing difficulty
Time course: when a seizure would happen if it happens
Seizures from psilocybin, when they occur, cluster around the peak of the drug's effect. Psilocin reaches peak plasma concentration roughly 60 to 90 minutes after ingestion, and the psychoactive window runs 4 to 6 hours. The table below maps the timeline.
| Time after ingestion | Drug phase | Seizure relevance |
|---|---|---|
| 0–15 minutes | Onset, minimal plasma levels | Very unlikely; nausea common |
| 15–45 minutes | Rising psilocin | Risk begins to climb |
| 45–90 minutes | Peak plasma concentration | Highest risk window |
| 90 minutes–3 hours | Plateau, main effects | Risk persists but lower |
| 3–6 hours | Decline | Risk falls toward baseline |
| 6–12 hours | Residual, afterglow | Essentially baseline in healthy users |
| Beyond 12 hours | Cleared | Unrelated to the dose |
The practical implication is that a seizure from mushrooms alone, if it happens, would almost certainly occur within the first 90 minutes. A person who is fine at hour three and has a seizure at hour twelve is having a different problem, and that deserves a medical workup rather than an assumption about the drug.
In plain terms: the dangerous window is short and sits near the peak. Supervision during the first two hours covers most of the theoretical risk.
Why the popular panic overstates the danger
Two misconceptions drive most of the fear, and both are worth correcting with numbers.
The first is that hallucinogens are broadly convulsant. They are not. Classic psychedelics including psilocybin, LSD, and mescaline are not classified as convulsants in pharmacology, and their seizure liability is far lower than that of stimulants, tramadol, or bupropion. A 2021 review of drug-induced seizures ranked psychedelics near the bottom of the risk list, well below alcohol withdrawal and antidepressants.
The second is that a bad trip equals a neurological event. A terrifying experience with panic, dissociation, and muscle tension can look alarming to bystanders, but panic attacks are not seizures. The distinction matters because the response differs: a panic attack needs calm reassurance and time, while a seizure needs airway protection and emergency assessment.
There is a real edge case worth naming. Serotonin syndrome, a rare reaction to serotonergic drug combinations, can include clonus and altered mental status that gets misread as seizure activity. It is not a seizure in the epileptic sense, but it is a medical emergency and is treated differently. Someone on an MAOI or high-dose SSRI who takes mushrooms and develops rigidity, fever, and rapid heart rate needs emergency care regardless of whether true seizure activity is present.
What to actually do: practical steps for lower risk
Risk reduction here is mostly about screening and setting, not about avoiding the drug entirely for people who choose to use it.
- Disclose lithium, epilepsy, and stimulant use to yourself honestly before dosing; those are the three biggest risk amplifiers.
- Avoid combining psilocybin with lithium, MAOIs, or stimulants; the interaction data is thin but the case reports are consistent.
- Do not dose while sleep-deprived or in alcohol withdrawal; both lower threshold independently.
- Have a sober person present for the first two hours, the peak-risk window.
- Know the seizure first-aid basics: protect the head, do not restrain, do not put anything in the mouth, time the event, call emergency services past 5 minutes.
- Start low if using at all; the dose-response for threshold effects is steep, so doubling a dose is not a linear increase in risk.
For anyone with epilepsy or a history of seizures, the honest advice is to avoid psilocybin outside a clinical setting that has specifically cleared it. No trial has established safety in that population.
Limitations of the evidence
The evidence base is weak in a specific way: it is rich in case reports and poor in denominators. We know seizures happen. We do not know the rate per thousand users, because nobody has counted the users. The controlled-trial data is clean but comes from screened healthy volunteers, a population deliberately chosen to exclude exactly the people at highest risk.
This means the reassuring numbers apply to healthy adults and should not be generalized to people with epilepsy, lithium users, or polysubstance users. The real-world risk in those groups is almost certainly higher than any published figure suggests, and the case reports support that reading even if they cannot quantify it.
What would settle the question is a prospective cohort with standardized seizure ascertainment. Until that exists, the most defensible position is that psilocybin alone carries a low but nonzero seizure risk in healthy users, a meaningfully higher risk in people with lowered seizure thresholds, and a specific dangerous interaction with lithium that deserves wider awareness than it currently gets.